Pay in 4 interest-free payments of $5.85 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
Pivotal Phase 3 trials Trial SURMOUNT-1 (NEJM 2022) Population 2,539 adults, obesity, no diabetes
Abbreviations PD: Parkinsons disease CNS: Central nervous system SCFA: Short-chain fatty acid TLR: Toll-like receptor LPS: lipopolysaccharide BBB: Bloodbrain barrier HDAC: Histone deacetylase REM: Rapid eye movement SNpc: Substantia nigra pars compacta ENS: Enteric nervous system GI: Gastrointestinal ROS/RNS: Reactive oxygen and nitrogen species FMT: Fecal microbiota transplantation GALT: Gut-associated lymphoid tissue AHR: Aryl hydrocarbon receptor SAAs: Seed-amplification assays TNF-: Tumor necrosis factor-alpha References Su D, Cui Y, He C, Yin P, Bai R, Zhu J, et al
Some clinicians find that patients can maintain results on mid-range tirzepatide doses after losing weight at higher doses
The OASIS 4 data is solid, and the prediabetes reversal rate is clinically meaningful
Insurance Coverage : Coverage varies widely
US$ 25.60
US$ 21.53
US$ 26.36
US$ 23.45
